gms | German Medical Science

76th Annual Meeting of the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery

German Society of Oto-Rhino-Laryngology, Head and Neck Surgery

04.05. - 08.05.2005, Erfurt

Article

Send article

Intratumoral application of trispecific antibody in patients with SCCHN

Meeting Abstract

Search Medline for

  • corresponding author K. Kolbow - Universitätsklinikum Schleswig-Holstein, Klinik für HNO, Lübeck
  • H. Frenzel - Universitätsklinikum Schleswig-Holstein, Klinik für HNO, Lübeck
  • F. Hoppe - Klinik für Hals-, Nasen- und Ohrenheilkunde des Klinikums Oldenburg, Oldenburg

Deutsche Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie. 76. Jahresversammlung der Deutschen Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie e.V.. Erfurt, 04.-08.05.2005. Düsseldorf, Köln: German Medical Science; 2005. Doc05hno627

The electronic version of this article is the complete one and can be found online at: http://www.egms.de/en/meetings/hno2005/05hno160.shtml

Published: September 22, 2005

© 2005 Kolbow et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.

Outline

Text

The tri-functional monoclonal antibody removab® (BIU III) represents a new concept of immuntherapeutic treatment for EpCAM-overexpressing epithelial tumors. BIU III is an intact bispecific monoclonal antibody with specificities against EpCAM and CD3. In addition, it binds to Fc-receptors of distinct blood cells and is therefore called „tri-functional“ antibody. Its principle was shown to result in efficient eradication of tumor cells by accessory cell-induced phagocytosis, T-cell mediated lysis and apoptosis.

Four patients with SCCHN were treated with BIU III and received 2 or 3 intratumoral applications of removab at intervals of 3 days. The vital signs were frequently monitored during and for 24 h after the administration of the BIU III. Serial blood samples were drawn from patients before, immediately after and 4, 12, and 24h after intratumoral application of BIU III. Concentrations of circulating lymphocyte subsets and interleukin (IL)-2, IL-4, IL-5, IL-10, IL-12, IL-18, GM-CSF, IFN- and TNF- were determined using enzyme-linked immunosorbent assay and flow cytometric analysis. All patients tolerated the treatment generally well, without reaching dose-limiting toxicity, liver enzymes were reversibly induced due the cytokine release syndome.

The immunological parameters have shown a massive increase in immunorelevant cytokines IL6/TNF- leading to an activated immune system e.g. IL-2, equally a significant increase of CD4/CD8 T-cells and activated cells CD4/CD25 and CD8/HLA-DR in peripheral blood.

Supported by: Fresenius Haemocare; Klara-Kreitz-Stiftung